Craig Saffer1, Gayle Olson2, Kim A Boggess3, Richard Beyerlein4, Charles Eubank5, Baha M Sibai6. 1. West Coast OB/GYN, 7910 Frost St., Suite 400, San Diego, CA 92123, United States. Electronic address: csaffer@pol.net. 2. University of Texas Medical Branch, 3.400 Old John Sealy, 301 University Blvd, Galveston, TX 77555, United States. Electronic address: golson@utmb.edu. 3. University of North Carolina, 3010 Old Clinic Blg, Chapel Hill, NC 27599, United States. Electronic address: kim_boggess@med.unc.edu. 4. Clinical Trials of America, 10 Coburg Rd., Eugene, OR 97401, United States. Electronic address: rbeyerlein@ctofa.com. 5. Advanced Research Associates, 5920 Saratoga Boulevard, Corpus Christi, TX 78414, United States. Electronic address: eubank@araresearch.com. 6. The University of Texas Medical School at Houston, 6431 Fannin, MSB 3.286, Houston, TX 77030, United States. Electronic address: nbist@aol.com.
Abstract
OBJECTIVE: To identify a reference range for placental growth factor (PlGF) in normotensive women without symptoms or signs of preeclampsia. STUDY DESIGN: Comprising the study cohort were 247 term pregnancies without preeclampsia or adverse neonatal outcomes from 16 sites in the US and Canada. Serial plasma samples were collected in 6 gestational age (GA) intervals between 20+0 and 40+0weeks. Non-parametric percentiles of the distribution of PlGF were estimated in each GA interval and a parametric model was developed to describe the distribution of PlGF as a continuous smooth function of GA (from 20 to 40weeks) in normal healthy pregnancy. Demographic and clinical factors influencing PlGF levels were also examined. RESULTS: There were 1366 evaluable samples collected from 247 subjects (242, 238, 226, 223, 222, and 215 samples in each GA interval, 20-24, 24-29, 29-32, 32-35, 35-37, and 37-40weeks, respectively). The 5th percentile of PlGF was 76.4, 141.1, 139.3, 65.5, 31.7, and 23.4pg/mL in each respective GA interval. The distribution of PlGF is approximately log normal with parameters that vary continuously as a function of GA. PlGF distribution is weakly dependent on maternal age, race/ethnicity, parity, and maximum systolic blood pressure (taken between weeks 20 and 24). Although statistically significant, these factors did not modify PlGF levels by more than ±15%. CONCLUSION: These data provide a valid reference range for PlGF in normal pregnancy.
OBJECTIVE: To identify a reference range for placental growth factor (PlGF) in normotensive women without symptoms or signs of preeclampsia. STUDY DESIGN: Comprising the study cohort were 247 term pregnancies without preeclampsia or adverse neonatal outcomes from 16 sites in the US and Canada. Serial plasma samples were collected in 6 gestational age (GA) intervals between 20+0 and 40+0weeks. Non-parametric percentiles of the distribution of PlGF were estimated in each GA interval and a parametric model was developed to describe the distribution of PlGF as a continuous smooth function of GA (from 20 to 40weeks) in normal healthy pregnancy. Demographic and clinical factors influencing PlGF levels were also examined. RESULTS: There were 1366 evaluable samples collected from 247 subjects (242, 238, 226, 223, 222, and 215 samples in each GA interval, 20-24, 24-29, 29-32, 32-35, 35-37, and 37-40weeks, respectively). The 5th percentile of PlGF was 76.4, 141.1, 139.3, 65.5, 31.7, and 23.4pg/mL in each respective GA interval. The distribution of PlGF is approximately log normal with parameters that vary continuously as a function of GA. PlGF distribution is weakly dependent on maternal age, race/ethnicity, parity, and maximum systolic blood pressure (taken between weeks 20 and 24). Although statistically significant, these factors did not modify PlGF levels by more than ±15%. CONCLUSION: These data provide a valid reference range for PlGF in normal pregnancy.
Authors: Jacqueline G Parchem; Keizo Kanasaki; Megumi Kanasaki; Hikaru Sugimoto; Liang Xie; Yuki Hamano; Soo Bong Lee; Vincent H Gattone; Samuel Parry; Jerome F Strauss; Vesna D Garovic; Thomas F McElrath; Karen H Lu; Baha M Sibai; Valerie S LeBleu; Peter Carmeliet; Raghu Kalluri Journal: J Clin Invest Date: 2018-10-08 Impact factor: 14.808
Authors: Martijn F Hoes; Zoltan Arany; Johann Bauersachs; Denise Hilfiker-Kleiner; Mark C Petrie; Karen Sliwa; Peter van der Meer Journal: Nat Rev Cardiol Date: 2022-01-11 Impact factor: 49.421
Authors: Kate Wiles; Kate Bramham; Paul T Seed; Lesia O Kurlak; Hiten D Mistry; Catherine Nelson-Piercy; Liz Lightstone; Lucy C Chappell Journal: Kidney Int Rep Date: 2019-03-26